A 52-year-old woman with known HFrEF (LVEF 28%) on optimal medical therapy (ACE inhibitor, beta-blocker, MRA) presents with persistent dyspnea and fatigue. She denies chest pain or syncope. Echocardiography shows no change from baseline. BNP is 680 pg/mL. To assess candidacy for advanced therapies (CRT or LVAD) and guide prognosis, which investigation is most appropriate?

## Hemodynamic Assessment in Advanced Heart Failure **Key Point:** Right heart catheterization (RHC) is the gold standard for hemodynamic assessment in HFrEF patients being considered for advanced therapies (CRT, LVAD, transplantation) and for prognostic stratification. ## Why Right Heart Catheterization is the Answer ### Clinical Context This patient has: - Severe HFrEF (LVEF 28%) on guideline-directed medical therapy (GDMT) - Persistent symptoms despite optimization - No acute decompensation or cardiogenic shock - Need for assessment of candidacy for device therapy or transplantation ### Hemodynamic Parameters Obtained by RHC | Parameter | Normal | Significance in HF | |---|---|---| | Right atrial pressure (RAP) | 2–8 mmHg | Elevated = RV dysfunction, volume overload | | Pulmonary artery pressure (PAP) | 15–30 mmHg systolic | Elevated = pulmonary hypertension | | Pulmonary capillary wedge pressure (PCWP) | 6–12 mmHg | Elevated = LV filling pressure, congestion | | Cardiac output (CO) | 4–8 L/min | Low = cardiogenic shock, poor prognosis | | Cardiac index (CI) | 2.5–4 L/min/m² | Low CI = severe HF, transplant candidate | | Pulmonary vascular resistance (PVR) | <2 Wood units | Elevated PVR = transplant contraindication risk | **High-Yield:** RHC is indicated in HFrEF patients with: - Consideration for transplantation or LVAD - Unclear volume status (diuretic resistance) - Suspected pulmonary hypertension - Need for prognostic stratification ### Prognostic Value Hemodynamic parameters predict outcomes: - **Low cardiac index (CI < 2.2)** = worse prognosis, transplant candidate - **Elevated PCWP (> 18 mmHg)** = congestion, need for diuretics - **Elevated PVR (> 3 Wood units)** = increased risk post-transplant **Clinical Pearl:** In this patient, RHC will determine whether she is a candidate for CRT (if not already done) or LVAD, and will stratify her risk for progression to cardiogenic shock or need for transplantation. ## Why Other Investigations Are Not First-Line **Stress echocardiography** — Assesses inducible ischemia and reserve; not indicated in stable HFrEF without angina or ischemic features. **Cardiac MRI with viability** — Useful for determining if revascularization may improve function (ischemic cardiomyopathy with viable myocardium); does not assess hemodynamics or guide device candidacy. **Coronary angiography** — Indicated if ischemic heart disease is suspected or if revascularization is being considered; not routine in stable HFrEF on GDMT. ```mermaid flowchart TD A[HFrEF on GDMT with persistent symptoms]:::outcome --> B{Candidate for advanced therapy?}:::decision B -->|Yes| C[Right heart catheterization]:::action B -->|No| D[Optimize medical therapy] C --> E{Hemodynamics acceptable?}:::decision E -->|CI > 2.2, PVR < 3| F[CRT or LVAD candidate]:::outcome E -->|CI < 2.2 or PVR > 3| G[Transplant evaluation or palliative care]:::outcome D --> H[Continue GDMT + monitoring]:::action ``` **Mnemonic — RHC Indications in HF (PUMP):** - **P**ulmonary hypertension assessment - **U**nclear volume status - **M**echanical support (LVAD/transplant) candidacy - **P**rognosis stratification